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Abstract
Background: FOXL2 is a transcription factor essential for ovarian development and maintenance. It is mutated in the
genetic condition called Blepharophimosis Ptosis Epicantus inversus Syndrome (BPES) and in cases of isolated premature
ovarian failure. We and others have previously shown that FOXL2 undergoes several post-translational modifications.
Methods and Principal Findings: Here, using cells in culture, we show that interference with FOXL2 SUMOylation leads to a
robust inhibition of its transactivation ability, which correlates with a decreased stability. Interestingly, FOXL2 SUMOylation
promotes its transient recruitment to subnuclear structures that we demonstrate to be PML (Promyelocytic Leukemia)
Nuclear Bodies. Since PML bodies are known to be sites where post-translational modifications of nuclear factors take place,
we used tandem mass spectrometry to identify new post-translational modifications of FOXL2. Specifically, we detected
four phosphorylated, one sulfated and three acetylated sites.
Conclusions: By analogy with other transcription factors, we propose that PML Nuclear Bodies might transiently recruit
FOXL2 to the vicinity of locally concentrated enzymes that could be involved in the post-translational maturation of FOXL2.
FOXL2 acetylation, sulfation, phosphorylation as well as other modifications yet to be discovered might alter the
transactivation capacity of FOXL2 and/or its stability, thus modulating its global intracellular activity.
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Introduction
FOXL2 is a conserved protein expressed in periocular, ovarian
and pituitary cells [1][2]. FOXL2 belongs to the family of
Forkhead transcription factors and is mutated in the Blephar-
ophimosis Ptosis Epicanthus inversus Syndrome (BPES) [3], a
genetic disorder characterized by eyelid malformations often
associated with premature ovarian failure [4]. Mutations of FOXL2
in cases of isolated premature ovarian failure have also been
reported [5][6]. It has recently been shown that somatic abla-
tion of Foxl2 induces transdifferentiation of adult mice ovaries
into testis-like structures [7], which is coherent with previous
observations from studies in knock-out mice [8][9]. These studies
show that FOXL2 is required during ovarian development and in
the adult to maintain the identity of the ovarian somatic cells. Very
recently, a somatic mutation of FOXL2 (p. C134W) was found in
.95% of ovarian granulosa-cell tumors [10]. Several high-
throughput studies have revealed that FOXL2 is involved in the
regulation of various cellular processes, including sterol/steroid
metabolism, cell stress response, apoptosis and reactive oxygen
species metabolism [11][12][13][14].
We and others have previously shown that FOXL2 undergoes
various post-translational modifications (PTM), including serine
phosphorylation and SUMOylation [12][15][16][17]. Moreover,
overexpression of the histone deacetylase SIRT1 leads to alterations
in the transactivation capacity of FOXL2, suggesting its acetylation
[12]. FOXL2 appears to have various and sometimes antagonistic
roles towards processes such as granulosa cells proliferation,
differentiation and apoptosis [18]. It has thus been proposed that
the variety of combinations of PTM isoforms might help explain
how FOXL2 can specifically regulate such different processes
[18][19].Thestudyofthe mechanismsofFOXL2post-translational
maturation might thus be of crucial interest to better understand
ovarian organogenesis, function and neoplasia.
Members of the Small Ubiquitin-related MOdifier (SUMO)
family of ubiquitin-like proteins act as PTM moieties on target
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vertebrates (SUMO1-4), and share substantial sequence homo-
logy [20]. Similarly to ubiquitin, SUMO proteins undergo
cleavage after a diglycine motif by SUMO-activating enzymes
(E1). Activated SUMO is then covalently linked to UBC9 (E2), the
only SUMO-conjugating enzyme described thus far, and subse-
quently attached to the e-amino group of target lysine residues
[20]. A third enzyme (E3 ligase), forming a complex with SUMO-
conjugated UBC9 and a SUMOylatable substrate, enhances the
efficiency and specificity of SUMO transfer. Conjugation to
SUMO is reversible and deSUMOylation is catalyzed by SUMO-
specific peptidases (SENPs) [22].
SUMOylation of transcription factors leads mostly to transcrip-
tional repression by participating to the recruitment of histone
deacetylases (HDAC) and subsequent heterochromatinization
of target genes, as well as the formation and recruitment of
transcriptional repressor complexes [23][24][25]. In a few cases,
SUMOylation has been reported to increase the activity of
transcription factors, such as the heat shock factors HSF1 and
HSF2 [26][27], NFAT1 [28], SOX9 [29], JunB [30] and RORa
[31].
SUMOylation has been associated to Promyelocytic Leukemia
(PML) Nuclear Bodies (PML NBs), which are stable nuclear
domains enriched in PML and SP100 proteins [32][33]. Van
Damme and collaborators have referenced more than 170 proteins
recruited to PML NBs, with functional implications in cell cycle,
apoptosis, tumorigenesis, regulation of transcription, DNA dam-
age response, etc [34]. However, the precise molecular function of
PML NBs remains poorly understood [35][36][37][38].
We have previously shown the existence of a FOXL2 SUMO1-
conjugate [12]. Two recent reports have confirmed FOXL2
SUMOylation and suggested that lysines 25, 114 and 150 may be
major conjugation sites [16][17]. Moreover, FOXL2 was also
found to directly interact with UBC9 and with the E3 SUMO-
protein ligase PIAS1. FOXL2 is known to repress the expression
of the steroidogenic acute response (StAR) gene [39] and its
SUMOylation increases the extent of repression [16][17].
SUMOylation alters the long-term fate of the target proteins
even though the SUMO moiety can be rapidly deconjugated
[23][20]. Here, we set out to explore the biological significance of
FOXL2 SUMOylation and found it to enhance its transcriptional
activity via its transient recruitment to PML NBs. These
subnuclear compartments could act as ‘modification factories’
for FOXL2, by bringing FOXL2 to the vicinity of locally
concentrated modification enzymes. We have indeed identified
eight new sites of post-translational modifications of FOXL2 by
mass spectrometry, further revealing the complexity of FOXL2
protein maturation.
Results and Discussion
SUMOylation of FOXL2 modulates its transactivation
ability
We have previously shown that FOXL2-SUMO1 conjugates
are endogenously present in granulosa and granulosa-like cells
(AT29C and KGN cells) and pituitary-derived aT3 cells [12].
Here, in order to explore the functional role of FOXL2-SUMO1
conjugates and their products, we first measured the impact on
FOXL2 activity of an interference with the global SUMOylation
process in human granulosa-like KGN cells [40]. Specifically, we
measured variations of the transactivation ability of transfected
FOXL2 in response to either overexpression of the SUMO-
deconjugating enzyme SENP2 or inhibition of SUMO-conjuga-
tion through the expression of a dominant-negative form of UBC9
(UBC9-DN; [41]). We assessed the activity of FOXL2 through its
effect on the promoter of the genes SOD2 and Per2. SOD2 (or
MnSOD) codes for an enzyme involved in the metabolism of
reactive oxygen species (ROS), whereas Per2 is a member of the
Period gene family and is expressed in a circadian pattern. Both
genes are directly regulated by FOXL2 in KGN cells [12][42] and
have previously been linked to tumor suppression [43][44].
Interestingly, SENP2 and UBC9-DN overexpression both strongly
decreased FOXL2 transactivation on the reporters pSODluc-3340
and Per2-luc (Fig. 1). These results suggest that SUMOylation of
FOXL2 is required to ensure a normal transcriptional activity, but
do not exclude the possibility of indirect effects (e.g. deSUMOyla-
tion of other transcription factors). A previous study showed that
no FOXL2 SUMOylation was detectable in transfected COS-7
cells when lysine residues 25, 87, 114 and 150 of FOXL2 were
mutated into arginines ([17], FOXL2-KFULL construct). We
therefore compared the transactivation ability of this mutant to the
one of wild-type FOXL2 (FOXL2-WT). Promoter activation by
FOXL2-KFULL was indeed significantly lower than the activa-
tion elicited by FOXL2-WT, with a more pronounced effect
on the Per2 promoter (Fig. 2A–B). However, the transactivation
ability of the KFULL mutant remained higher than what we
observed when we overexpressed, for example, UBC9-DN. This
might mean that SUMOylation increases FOXL2 activity through
both direct and indirect ways, or that the KFULL mutant can still
undergo some SUMOylation, though at a hardly detectable level.
Previous studies using the KFULL mutant showed that trans-
repression by FOXL2 on the Steroidogenic Acute Response (StAR)
promoter was also enhanced by SUMOylation [16][17]. To
rationalize that both activation and repression are modulated by
SUMOylation, we hypothesize that SUMOylation may increase
the stability of FOXL2. To test this idea in our conditions, we
overexpressed FOXL2 alone or in combination with UBC9-DN in
KGN cells. Cells were cotransfected with a control vector driving
the expression of a non-relevant HSV-tagged 15 kDa protein
(referred to as ‘‘Lic-‘‘) to check the efficiency of transfection
(Fig. 2C). As expected, overexpression of UBC9-DN led to a 50%
decrease of the FOXL2 protein level, which is to be correlated
with its absence of transactivation ability in these conditions.
However, a contribution of a modification of FOXL2 properties
such as reduced DNA-binding or intrinsinc transactivation
capacity cannot be excluded. Indeed, the stability of the KFULL
mutant in KGN cells was only slightly lower than that of the
WT (Fig. 2D), despite a marked difference in their transactivation
abilities. This suggests that a modification of the intrinsic pro-
tein properties contributes to the loss of transactivation when
SUMOylation is impaired.
SUMOylation of FOXL2 induces its localization to
subnuclear structures
To investigate whether SUMOylation had an impact on the
subcellular distribution of FOXL2, we generated a construct
driving the overexpression of a tripartite fusion protein involving,
from N- to C-terminus, human SUMO1, FOXL2 and the GFP
(hereafter called SUMO-FOXL2-GFP). Next, we transfected the
FOXL2-GFP vector alone (control), FOXL2-GFP along with a
SUMO1 expression vector, and our SUMO-FOXL2-GFP fusion
vector into COS-7 cells, which have been extensively used to
follow FOXL2 subcellular localization owing to their easy
transfection [45][46][47]. Interestingly, transfection of the tripar-
tite fusion construct led to high proportions of cells displaying
subnuclear structures containing high local concentrations of GFP-
fused proteins (Fig. 3A). These structures were also observed in
some cells transfected with the FOXL2-GFP-expressing construct,
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only GFP is expressed and localized to the nucleus. This shows
that the presence of these structures does not result from a bias
induced by the GFP tag (Fig. 3A). To verify that this localization of
SUMOylated FOXL2 was not cell-line specific, we also overex-
pressed FOXL2-GFP or SUMO-FOXL2-GFP in KGN cells, in
which we conducted the functional studies. As expected, FOXL2-
GFP was mainly diffuse in the nucleus, whereas SUMO-FOXL2-
GFP was enriched in subnuclear domains similar to those
observed in COS-7 cells (Fig. 3B).
To further demonstrate that SUMOylation of FOXL2 promotes
its recruitment to these structures, we expressed FOXL2-GFP alone
or in combination with SUMO1 or SENP2, and determined
the percentage of COS-7 cells displaying FOXL2 nuclear bodies
(Fig. 3C). As expected, we observed an increase of the proportion of
cells displaying nuclear bodies when SUMO1 was overexpressed
from 15 to 25%, and a reduction when SENP2 is overexpressed,
from 15tolessthan 5%.More than40%ofcellstransfected withthe
tripartite fusion construct displayed visible nuclear bodies. We also
compared cells transfected with FOXL2-WT or FOXL2-KFULL
mutant in fusion with the GFP, alone or with SUMO1. When
FOXL2 (WT or KFULL) was expressed alone, about 15% of
transfected cells displayed these bodies. However, when SUMO1
was co-overexpressed, the proportion of cells with visible nuclear
bodies increased to 25% only for cells expressing FOXL2-WT,
whereas there was no significant increase among KFULL
expressing cells (Fig. 3C). This suggests that FOXL2 might be
recruited to these structures independently of its SUMOylation (see
discussion below) but also shows that FOXL2 SUMOylation
enhances the frequency of appearance of these bodies.
It is worth mentioning that we failed to observe any obvious
cytoplasmic localization of FOXL2-WT-GFP, FOXL2-KFULL-
GFP or the single point mutants (K25R, K87R, K114R, K150R;
data not shown). This suggests that the amount of cytoplasmic
protein remains below our detection level, which also suggests that
the lowered activity of the FOXL2-KFULL mutant noticed above
is not due to a trivial mislocalization of FOXL2.
FOXL2 is transiently recruited to PML Nuclear Bodies
(PML NBs)
To explore whether or not these NBs contained diffusible or
immobilized FOXL2 and to rule out any potential aggregation, we
assessed FOXL2 mobility using Fluorescence Recovery After
Photobleaching (FRAP) in COS-7 cells. Specifically, we transfect-
ed these cells with either FOXL2-GFP, FOXL2-GFP and
SUMO1, or the vector expressing the tripartite fusion protein
SUMO1-FOXL2-GFP. We then determined the time required
to recover 50% of the maximum fluorescence (t1/2) after
Figure 1. Interference with SUMOylation decreases FOXL2 transactivation. A and B) Luciferase assays in KGN cells transfected with Per2-luc
and pSODluc-3340 (40 ng/well), respectively, with or without FOXL2 and SENP2 overexpression (each 20 ng/well). C and D) Luciferase assays in KGN
cells transfected with Per2-luc and pSODluc-3340 (40 ng/well), respectively, with or without FOXL2 and UBC9-DN overexpression (each 20 ng/well).
Each value is representative of six biological replicates. Error bars represent the standard error of the mean (SEM). Statistical significance in Student t-
tests: n.s.: p.0.05, *: p,0.05, **: p,0.01, ***: p,0.001. All experiments were repeated at least three times with consistent results.
doi:10.1371/journal.pone.0025463.g001
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mobility. For each cell, we bleached both a nucleoplasmic region
and a nuclear structure enriched in FOXL2 (when relevant), to
assess a potentially differential mobility (Fig. S1). We found that
FOXL2-GFP alone displayed an average t1/2 of 9.3 s (61.7 s), a
value compatible with what we have previously reported [47].
This value was not significantly different from that of GFP-fused
proteins in the nucleoplasmic portions of cells co-expressing
FOXL2-GFP and SUMO1 or the tripartite fusion protein
(respectively 10.3 s64.3 s and 7.2 s61.7 s). Recovery of fluores-
cence did not show statistically significant differences of protein
mobility the nuclear structures of the co-transfected cells and of
cells transfected with the tripartite fusion construct (respectively
6.8 s61.4 s and 5.2 s60.8 s).
To further characterize the subnuclear structures enriched in
SUMOylated FOXL2, we performed immunofluorescence exper-
iments on COS-7 cells co-transfected with FOXL2-GFP and
SUMO1 expression vectors with antibodies recognizing well-
characterized subnuclear structures. No colocalization was ob-
served with components of nuclear speckles, transcription
factories, gems or Cajal bodies (Fig. S2) (see refs. [48][49][50]
for reviews on these structures). Interestingly, SUMO FOXL2
bodies were stained by an anti-PML antibody (Fig. 4A). These
structures being PML NBs is coherent with the observation that
they are also enriched in SUMO1 (Fig. 4B). Interestingly, we have
performed a FOXL2 two-hybrid screen using a mouse ovary
cDNA library which retrieved a potential interaction between
FOXL2 and the E3 SUMO-protein ligase PIAS2 (2 prey clones),
the SUMO-conjugating enzyme UBC9 (2 prey clones) and the
nuclear autoantigen SP100, which is an organizer of PML-NBs (2
clones). These results suggest that PIAS2 is involved in FOXL2
SUMOylation and confirm previous findings on the interaction
between FOXL2 and UBC9 [16]. At the same time the latter
finding lends credence to our two-hybrid screening. Next, we
decided to further validate the interaction between FOXL2 and
SP100. We therefore coexpressed FOXL2-GFP with SUMO1 and
an HSV-tagged version of SP100A (the most abundant form of
SP100). Immunodetection of SP100 showed that it colocalized
with FOXL2, further emphasizing that the latter is recruited to
PML NBs (Fig. 4B). Furthermore, SP100 could be co-immuno-
precipitated with FOXL2 (either WT or KFULL, Fig. 4C),
suggesting that a direct interaction with SP100 may be a way to
recruit FOXL2 to PML NBs. We tried to co-immunoprecipitate
endogenous PML with FOXL2 but failed to find any direct
Figure 2. Enhanced stabilisation of FOXL2 partially explains the transcriptional effect of SUMOylation. A and B) Luciferase assays in
KGN cells transfected with Per2-luc and pSODluc-3340 (40 ng/well), respectively, with or without FOXL2-WT or FOXL2-KFULL overexpression (20 ng/
well). Each value is representative of six biological replicates. Error bars represent the SEM. Statistical significance in Student t-tests: n.s.: non-
significant, *: p,0.05, **: p,0.01, ***: p,0.001 C) Western blot of whole cell extracts of KGN cells transfected with or without FOXL2-V5 and myc-
UBC9-DN (each 1 ug/well in a 6 well plate), using pcDNA3.1 as a mock vector. Lic- (expressing a fusion protein His-Tag:S-Tag:HSV-Tag:His-Tag) was
used as an internal transfection control (500 ng/well). First panel: FOXL2. Second panel: Lic- (anti-HSV). Third panel: UBC9-DN (anti-myc). Below
second panel is indicated the relative intensity of the FOXL2 band compared to the Lic- band. D) Western blot of whole cell extracts of KGN cells
transfected for 24 h with or without FOXL2-WT-V5 or FOXL2-KFULL-V5 (2 mg/well in a 6-well plate). Lic- (500 ng) was used as a transfection control.
First panel: FOXL2. Second panel: Lic- (anti-HSV). Below second panel is indicated the relative intensity of the FOXL2 band compared to the Lic- band.
All experiments were repeated at least three times with consistent results.
doi:10.1371/journal.pone.0025463.g002
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e25463Figure 3. SUMOylation promotes FOXL2 recruitment to subnuclear structures. A and B) Presence of nuclear structures displaying high
FOXL2-GFP concentration in a climate of high SUMOylation. Micrographs of COS-7 cells (A) and KGN cells (B) expressing FOXL2-GFP, the tripartite
SUMO-FOXL2-GFP fusion or NLS-GFP, as indicated. Left column: GFP. Right column: Hoechst 33342 DNA staining. First line shows a representative
‘‘normal’’ cell, where FOXL2 displays its most common localisation, superimposable to DNA. Second and third lanes show representative cells with
‘‘FOXL2 nuclear bodies’’ where FOXL2 is enriched in subnuclear structures clearly distinct from chromatin structures. Fourth lane (only in A) shows a
typical cell stained with nuclear localised GFP. Scale bar: 5 mm. Scale bar is valid for all micrographs. (C) Quantification of cells presenting subnuclear
structures in COS-7 expressing SUMO-FOXL2-GFP, FOXL2-WT-GFP or FOXL2-KFULL-GFP with or without overexpression of SUMO1 or SENP2. At least
300 GFP-positive cells were scanned per condition (in groups of 50 to estimate the standard deviations). Error bar: SEM. Letters a, b, c, d refer to
statistical categories in a Student’s t-test. Conditions with different letters are statistically different with p,0.05.
doi:10.1371/journal.pone.0025463.g003
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that only SUMOylated FOXL2 may interact with the SUMO-
binding domain of PML. To further study the mode of
recruitment of FOXL2 to PML NBs, we overexpressed SP100
or two isoforms of PML (IV and V) tagged with RFP along with
FOXL2 and SUMO1 and counted the number of cells displaying
NBs (Fig. 4D). Overexpression of SP100 had no marked effect on
FOXL2 localization or PML NBs organization, except a marginal
reduction of the proportion of cells with NBs. This probably
means that endogenous SP100 is not a limiting factor for PML
NBs formation and FOXL2 recruitment. Surprisingly, overex-
pression of either PML isoform almost fully abrogated localization
of FOXL2 to PML NBs (i.e. 25% to 3–4% of cells). No
colocalization of FOXL2 and these PML isoforms could be
observed (not shown). Furthermore, PML NBs generally seemed
disorganized, enlarged and the amount of soluble PML seemed
lower than in non-transfected cells (Fig. 4E). This might be due to
non-functional aggregation of PML proteins due to an excess of
protein or to an imbalance between isoforms. Indeed, it has been
shown that expression different PML isoforms in a PML null
background led to very different PML NBs, suggesting that
expression of specific isoforms may influence the formation and
structure of PML NBs [51]. Based on this result, we decided to test
the effect of the overexpression of PML-V on FOXL2 transactiva-
tion ability. We found that it completely abolished the activation
by FOXL2 of either SOD2 or Per2 promoters (Fig. 4F–G).
Furthermore, the stability of FOXL2 was severely impaired by
PML-V overexpression (Fig. 4H). These results suggest that well-
organized PML NBs are necessary for the stabilization/activation
of FOXL2. These results taken together allow us to propose that
the effect of FOXL2 SUMOylation is mainly to promote its
recruitment to PML NBs.
Mapping of the post-translational modifications of
FOXL2 by mass spectrometry
SUMOylation is a transient modification, affecting a small
percentage of a particular protein at a time. We therefore
hypothesized that SUMOylation, which mediates FOXL2 recruit-
ment to PML NBs, might also mediate its further post-
translational processing, which would explain the alteration of
FOXL2 activity observed when SUMOylation is impaired. Here,
we have mapped some of these PTMs by mass spectrometry, in
order to test if non-modifiable mutants may recapitulate the
inactivation of FOXL2 observed through inhibition of its
SUMOylation. We performed an immunoprecipitation of
FLAG-tagged FOXL2 transiently overexpressed in COS-7 cells,
whose easy transfection allowed us to recover the required amount
of protein. We first tested the presence of specific modifications of
FOXL2 in our samples by Western blot using antibodies targeting
phosphorylated serine, threonine and tyrosine residues and
acetylated lysines (Fig. 5A). All antibodies recognized a 51–
52 kDa band when FOXL2 was immunoprecipitated but not in
the control, showing that FOXL2 undergoes these modifications.
We then performed tandem mass spectrometry on FOXL2
peptides, using an Orbitrap analyzer. To maximize sequence
coverage, we used both tryptic and chymotryptic treatments and
we used both direct digestion of affinity purified FOXL2, which
avoids the biases due to SDS-PAGE and in-gel digestion. At least
two independent analyses were conducted for each digestion
mode. Databases were searched using SEQUEST and Mascot
engines, with phosphorylation and acetylation set as dynamic
modifications. We obtained an excellent coverage (97%) of
the FOXL2 sequence (Fig. 5B), with multiple matches for
most peptides (Table S1). Many phosphorylated peptides were
identified by both search engines in multiple spectra (Fig. 5B,
Table 1 and Table 2). Serine 33 was independently found in 7
types of peptides with a +80 Da mass shift, with one peptide where
it was the only phosphorylatable residue (Table 1, Table 2 and Fig.
S3). Peaks typical of phosphorylation, corresponding to the loss of
aH 3PO4 group (neutral loss of 98 Da) from the precursor were
observed in the MS/MS spectrum and confirmed the attribution.
Serine 238 was found in several peptides that could be
unambiguously attributed due to the neighboring polyalanine
domain that has a characteristic fragmentation pattern (Table 1,
Table 2 and Fig. S4). Peptides were found with and without a
+79.966 mass shift characteristic of phosphorylation and serine
238 was the only phosphorylatable residue in these peptides. Some
fragments with a 98 Da neutral loss were also visible. A third class
of phosphorylated peptides included serine 203, 211 and tyrosine
215 (Table 1, Table 2 and Fig. S5). Peaks corresponding to the loss
of one phosphate group from the precursor could be observed but
had a very low intensity, whereas peaks still bearing the phosphate
group were present. Serine 203 could be ruled out as the
phosphorylated residue because y-ion series clearly allowed us to
locate the phosphorylation near the C-terminus of the peptide.
However serine 211 and tyrosine 215 could not be discriminated.
The last class of phosphorylated peptides included serine residues
323, 326 and 339 as well as threonine 329 and 338 (Table 1,
Table 2 and Fig. S6). Non phosphorylated fragments were visible
in the MS/MS spectra, but the neutral loss was only partial and
peaks bearing the 80 Da modification were present. The b-series
of ions clearly allowed the localization of the phosphorylation site
near the N-terminus of the peptide. However, the peptide
(SPASPATAA) containing serines 323 and 326 and threo-
nine 329 was poorly fragmented, and the exact position of the
phosphorylation could not be assigned.
Another apparent phosphorylation site was identified at the N-
terminus of the protein, either at serine 4 or tyrosine 5 (Table 1,
Table 2 and Fig. S7). However, no neutral loss corresponding to
phosphorylation could be observed in the MS/MS spectra.
Moreover, in the group of spectra attributed to the peptides
having this modification, the precursor molecular weight had an
average difference of 25.5 ppm with respect to the predicted
mass, whereas the average difference for all the peptides was
0.1 ppm, with a standard deviation of only 1.2 ppm. This was
specific to the presence of the modification, as peptide matches
attributed to a peptide including serine 4 and tyrosine 5 and not
having a +80 Da modification had a measured mass correspond-
ing to the predicted mass. Two chymotryptic peptides (ASYPE-
PEDAAGAL and ASYPEPEDAAGALL) were identified with and
without the modification, allowing direct calculation of its mass
based on the measured precursor masses. The masses retrieved
were 79.956+/20.003 Da and 79.957+/20.001 Da respectively.
The only simple modification fitting this pattern is sulfation (or
sulfonation), which has mainly been described for tyrosines, but
also detected on serines and threonines [52][53]. This modifica-
tion usually produces a neutral loss of 80 Da in the fragmentation
spectra that unfortunately could not be observed in this
case. However, the b-ion series allowed us to map the 80 Da
modification to the SYPEPE part of the fragment. This
subfragment does not fragment correctly in the presence of the
modification. Moreover, doubly-charged b-ions seemed favored
when the modification was present, compared to singly-charged b-
ions, suggesting that intramolecular hydrogen bonds involving the
sulfate group may retain positive charges and stabilize the N-
terminal fragment.
Acetylated peptides were less abundantly identified than
phosphorylated peptides, but we found several potentially
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fragmentation spectra with spectra of the corresponding peptides
without acetylation (identified with high reliability) confirmed the
existence of a +42.010 Da moiety on the relevant peptides. The
first peptide involved lysine 96 (Fig. S8). It was only found in one
of the four conditions, but 2 spectra were attributed with good
scores in each of the replicates. Other acetylated peptides were
detected by only one match and involve lysine 140 (Fig. S9) and
366 (Fig. S10), respectively.
We next generated variants of FOXL2 bearing a mutation at
each one of the modified or potentially modified residues, in fusion
with the GFP. Mutations were designed to represent the
characteristics of the non-modified version of FOXL2, and thus
a (potentially) modified serine/threonine residue was replaced by
an alanine, a tyrosine by a phenylalanine and a lysine by an
arginine. We generated isolated mutants for each residue except
for serine 323 which was mutated along with serine 326, predicted
as a stronger phosphorylation site. We tested the transactivation
ability of such mutants on the Per2 and SOD2 promoters and
analyzed their subcellular localization in COS-7. Surprisingly, on
the Per2 promoter, all mutants were as active as FOXL2-WT
(Fig. 6A). A mild hyper-activation of FOXL2-S326A was detected
in some experiments but was highly variable. On the SOD2
promoter, some mutants tended to be slightly less active than
FOXL2-WT, but this difference was not statistically significant
(pmin=0.2, for S238A) (Fig. 6B). Again, a mild hyper-activation of
FOXL2-K366R was detected in some experiments but was
variable from one to another.
Coherently with these results, the subcellular localization of the
mutants was very similar to the localization of FOXL2-WT. No
cytoplasmic localization or aggregation could be observed in any
of the mutants. In addition, all mutants were able to localize to at
NBs (colocalizing with PML), similar to the ones observed with the
WT protein. Interestingly, the frequency of appearance of the
nuclear bodies was, however, altered for some mutants (Fig. 6C).
Indeed, FOXL2-S33A recruitment to NBs was as high as FOXL2-
WT recruitment to PML NBs when SUMO1 was overexpressed
(20% compared to 10% without SUMO1 overexpression).
Conversely, FOXL2-S326A was significantly less present in NBs
than FOXL2-WT expressed alone and not significantly different
from FOXL2-WT along with SENP2 overexpression. Other
mutants tended to be less present in PML NBs (S238A, Y215F,
K366R), but without statistical support. These results suggest that
phosphorylation at serines 33 and 326 may play a role in FOXL2
recruitment to or transient retention at PML NBs. As mutation of
these residues does not have a significant effect on FOXL2
transactivation ability, it seems that multiple and combinatorial
post-translational modifications are necessary to explain the long
term effects of SUMOylation. More extensive studies will be
necessary to decipher the precise role of each modification and the
functional interactions that may occur among multiple modifica-
tions. The mechanism by which SUMOylation stimulates FOXL2
transactivation remains largely unknown but our work shows that
Figure 4. FOXL2 recruitment to PML Bodies enhances its transactivation ability. A and B) FOXL2 colocalization with PML, SUMO1 and SP100
in nuclear bodies. COS-7 cells overexpressing SUMO-FOXL2-GFP, FOXL2-WT-GFP, FOXL2-KFULL-GFP or NLS-GFP (as indicated, green color) were stained
withananti-PML antibody (panelA,red) oran anti-SUMO1 anti-body (panel B,firstthreelines, red) Inthe fourthlineofpanel B,COS-7 cells overexpressing
FOXL2-WT-GFP and SP100A-HSVwere stained withan anti-HSV antibody.Representative cells withFOXL2 enriched in nuclear bodies are shown. DNA was
stained using Hoechst 33342 (in blue). Scale bar: 5 mm. Scale bar is valid for all micrographs. (C) Interaction between FOXL2 and SP100. SP100-HSV was
expressed alone (lane 1) or co-expressed with V5-tagged FOXL2-WT (lane 2) or KFULL (lane 3). FOXL2 was precipitated using anti-V5-conjugated affinity
resin for western blot analysis. Upper panel shows a 50 kDa band detected with anti-FOXL2 antibody. Second panel shows a 70 kDa band detected with
an anti-HSV antibody. Third and fourth panels display a western blot analysis of the lysates, with anti-FOXL2 and anti-HSV antibodies, respectively.( D )
Quantification of cells displaying subnuclear structures in COS-7 expressing SUMO-FOXL2-GFP or FOXL2-WT-GFP with or without overexpression of
SUMO1, PML-IV-RFP, PML-V-RFP or SP100A-HSV. At least 300 GFP-positive cells were scanned per condition (in groups of 50 to estimate the standard
deviations). Error bar: SEM. Letters a, b, c, d refer to statistical categories in a Student’s t-test. Conditions with different letters are statistically different with
p,0.05. (E) PML localisation in COS-7 or KGN cells overexpressing PML-V-RFP. Green: anti-PML directed against all isoforms of PML. Red: PML-V-RFP. Blue:
DNA stained with Hoechst 33342.In non-transfected cells, PML is mostly nucleoplasmic witha few dots (1–5 in COS-7 cells, 5–20 in KGNcells) indicativeo f
PML NBs. With PML-V-RFP expressed, PML NBs are much enlarged and the proportion of nucleoplasmic PML is decreased. Scale bar: 10 mm. Scale bar is
valid for all micrographs. F and G) Luciferase assays in KGN cells transfected with Per2-luc and pSODluc-3340 (40 ng/well), respectively, with or without
FOXL2 and PML-V-RFP overexpression (each 20 ng/well). Each value is representative of six biological replicates. Error bars represent SEM. Statistical
significance in Student t-tests: n.s.: p.0.05, *: p,0.05, **: p,0.01, ***: p,0.001. H) Western blot of whole cell extracts of KGN cells transfected with or
without FOXL2-V5 and PML-V-RFP (2 mg/well in a 6-well plate), using pcDNA3.1 as a mock vector. Lic- (expressing a fusion protein His-Tag:S-Tag:HSV-
Tag:His-Tag)wasusedasatransfectioncontrol(500 ng).Firstpanel:FOXL2.Secondpanel:Lic-(anti-HSV).Thirdpanel:PML-V(anti-HA).Belowsecondpanel
is indicated the relative intensity of the FOXL2 band compared to the Lic- band. All experiments were repeated at least three times withconsistent results.
doi:10.1371/journal.pone.0025463.g004
Figure 5. FOXL2 is acetylated and phosphorylated on multiple
residues. A) Western blot following anti-FLAG immunoprecipitation of
COS-7 lysates and SDS-PAGE. Cells were transfected with a mock vector
(pcDNA3.1) or FOXL2-FLAG. Independent immunoblots were performed
using anti-FOXL2 C-terminus antibody, mouse anti-acetyl-Lysine (Cell
Signaling Technologies), mouse anti-phospho-Serine, anti-phospho-
Threonine and anti-phospho-Tyrosine (Sigma-Aldrich), as indicated on
the left of each image. B) Schematic representation of FOXL2 post-
translational modifications identified by mass spectrometry. Immuno-
precipitated FOXL2, in the form of a crude eluate or the isolated 51–
52 kD band revealed by Coomasie staining, was digested using trypsin
or chymotrypsin and analyzed using ESI-MS-MS with an Orbitrap
analyser. Databases were searched with acetylation of lysines and
phosphorylation of serines, threonines and tyrosines set as dynamic
modification in addition of modification of cysteines by a carbamido-
methyl or n-ethylmaleimide groups and oxidation of methionine that
were due to sample preparation. FOXL2 sequence is represented by a
green and red bars, the green color representing residues present in at
least one high confidence peptide, whereas other residues are in red.
The positions of the phosphorylated and acetylated residues in the
FOXL2 sequence, based on the database search, are represented.
Manual inspection revealed that the modification on serine 4 or
tyrosine 5 is more likely a sulfation than a phosphorylation. Lower bar
represents the position of the forkhead and poly-Alanine domains.
doi:10.1371/journal.pone.0025463.g005
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likely to be part of this mechanism.
Conclusions
Here, we find that SUMOylation targets FOXL2 to PML NBs.
Interference with the SUMOylation machinery or PML NB
formation leads to a decrease of FOXL2 activity on two target
promoters potentially related to the role of FOXL2 in ROS
metabolism and tumor suppression. SUMO1-fused FOXL2 is
highly present in PML NBs and interference with SUMOylation
decreases the proportion of cells where FOXL2 colocalizes with
PML NBs. Interestingly, a direct interaction with the PML NB
scaffold protein SP100 may contribute to SUMO-independent
FOXL2 recruitment to these subnuclear structures.
PML NBs are enriched in a number of enzymes involved in the
PTM of proteins, including kinases, HATs, HDACs, SUMO-
and ubiquitin-ligases and methyl-transferases (Table 3). Thus,
post-translational maturation of FOXL2 would be a logical
consequence of its SUMOylation. Thus, we tried to map as much
post-translational modifications of FOXL2 as possible. We dete-
cted two phosphorylation sites on serines 33 and 238, one either
on serine 211 or tyrosine 215, and at least one in the cluster
composed of serines 323, 326 and threonine 329. Interestingly, the
GPS 2.1 tool predicts the six serine/threonine sites to be potential
targets of the CMGC group of kinases [54][55], which includes
cyclin-dependent kinases, mitogen-activated protein kinases, dual
specificity tyrosine-phosphorylation-regulated kinases and glyco-
gen-synthase kinases. Phosphorylation at serine-proline (SP) sites
could thus be a major aspect of FOXL2 post-translational
modification. Interestingly, LATS1, which is the only kinase
known to interact with FOXL2 thus far, also interacts with CDK1
to arrest early mitosis [56]. Phosphorylation of FOXL2 might then
be cell-cycle dependent and might in turn affect the modulation of
cell cycle by FOXL2. Phosphorylation at tyrosine 215 would also
be very interesting if confirmed. Indeed, the naturally-occuring
mutant pTyr215Cys is one of the very few disease-causing
substitutions in FOXL2 sequence located outside the forkhead
domain [57]. Further studies beyond the scope of this work will be
necessary to better understand the role of these phosphorylations.
The precision of the Orbitrap analyser also allowed us to detect
the potential sulfation of either serine 4 or tyrosine 5. The
functional meaning of sulfation on FOXL2 remains to be studied.
Indeed, tyrosine sulfation usually affects extracellular and secreted
proteins [58]. However, it has been reported as an extremely
abundant modification, which may suggest the existence of
substrates in various subcellular compartments. Serine/threonine
O-sulfation of a nuclear receptor has previously been described
[59], but very few studies have focused on this modification thus
far. Finally, we gathered evidence for acetylation on three lysine
residues, although the depth of detection was rather poor.
Interestingly, lysine 96 belongs to a consensus (K/RxKK) found
in many p300 targets [60] and we have previously shown that
p300 overexpression stimulates FOXL2 transactivation [12].
However, all these PTMs, at least studied separately, had very
little effect on FOXL2 transactivation ability. Thus,the functional
effects of their combinations deserve further attention.
PML NBs could play the role of catalysts for FOXL2
maturation by recruiting it to the vicinity of modifying enzymes.
However, little is known about the process of FOXL2 SUMOyla-
tion itself. The presence of a phosphorylation site after lysine 25,
evoking a phospho-dependent SUMOylation motif, may suggest a
role for FOXL2 phosphorylation in its SUMOylation. Further
studies extending our results on the PTMs of FOXL2 and their
potential modulation of its interaction with protein partners will be
of great interest.
Until now, SUMOylation of transcription factors has been
mostly associated with transcription repression, mainly through
recruitment of general transrepressor complexes that possess
SUMO interacting motifs [24]. However, a few exceptions have
been found where SUMO-conjugation is crucial to enhance the
transactivation ability of several transcription factors. Based on our
findings concerning FOXL2, we propose that SUMOylation may
Table 1. Peptides detected as modified by a phosphorylation, sulfation or acetylation using Mascot.
Peptide sequence Modification Modified residue digestion matches highest Score charge
APETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPY Phosphorylation Serine 33 Chymotrypsin 3 39 +5
APETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSY Phosphorylation Serine 33 Chymotrypsin 16 43 +5
LAPETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSY Phosphorylation Serine 33 Chymotrypsin 4 39 +4
EPEGPPPSPGK Phosphorylation Serine 33 Trypsin 20 50 +2
TVKEPEGPPPSPGK Phosphorylation Serine 33 Trypsin 13 65 +2
LNNSWPLPQPPSPMPY Phosphorylation Serine 211/
Tyrosine 215
Chymotrypsin 5 27 +2
NNSWPLPQPPSPMPY Phosphorylation Serine 211/
Tyrosine 215
Chymotrypsin 7 31 +2
AScQMAAAAAAAAAAAAAAGPGSPGAAAVVKGL Phosphorylation Serine 238 Chymotrypsin 6 50 +3
HAAAAPPPAPPHHGAAAPPPGQLSPASPATAAPPAPAPTSAPGLQF Phosphorylation Serine 323/Serine 326/
Threonine 329
Chymotrypsin 7 48 +3
MMASYPEPEDAAGAL Sulfation Serine 4/Tyrosine 5 Chymotrypsin 9 37 +2
MMASYPEPEDAAGALL Sulfation Serine 4/Tyrosine 5 Chymotrypsin 7 35 +2
MMASYPEPEDAAGALLAPETGR Sulfation Serine 4/Tyrosine 5 Trypsin 10 61 +3
KGWQNSIR Acetylation Lysine 96 Trypsin 2 65 +2
Each line represents a group of matches reaching our quality cut-off corresponding to the same peptide sequence with the indicated modification. Mascot matches
were selected to have a peptide score .20. Detail of all peptide matches (modified and unmodified) obtained by both search engines is available as supplementary
information (Table S1).
doi:10.1371/journal.pone.0025463.t001
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Materials and Methods
Ethics statement
Given that this study deals only with established cell lines
approval by an ethics committee was not required.
Mammalian cell expression and reporter vectors
The luciferase reporters pSODluc-3340 and Per2-luc (a
generous gift from Pr. Gad Asher) are pGL3-basic vectors, and
have been described previously [61][62]. Plasmid DNA for
SENP2 expression vector was a kind gift from Pr. Yanping Zhang
[63]. The UBC9-DN mammalian expression vectors were a gift
from Pr. Yin-Yuan Mo [41]. The FOXL2-GFP expression vector
was described previously, and KFULL-GFP was created using the
same protocol [47]. PML-IV-RFP and PML-V-RFP were kind
gifts from Dr Annie Sittler and Pr Richard Day, respectively [64].
FOXL2-FLAG was created by replacing the GFP coding region
by a 3XFLAG cassette using the XbaI and Kpn2I sites present in
the previous construct. The FOXL2-V5 and KFULL-V5
constructs were created using the pcDNA3.1/V5-His TOPO
TA Expression Kit (Invitrogen) according to manufacturer’s
instructions. The FOXL2-GFP N-terminal SUMO1 fusion
(SUMO1-FOXL2-GFP) was obtained by junction PCR as
described previously [47], using pFOXL2-GFP and a PCR-
amplified human SUMO1 coding region, and subsequent cloning
in frame with the GFP ORF in pCDNA3.1/CT-GFP (Invitrogen).
SP100A was amplified from pooled cDNAs from cultured cells
(HeLa, Jurkat, K562, KGN and COV434) and inserted in frame
with an HSV tag into pTriex4 Ek/LIC vector (Novagen),
according to the manufacturer’s instructions. Lic- (expressing a
fusion protein His-Tag:S-Tag:HSV-Tag:His-Tag) was created by
inserting a short DNA sequence (10 bp) in frame with the tags of
pTriex-4 Ek/LIC vector.
Table 2. Peptides detected as modified by a phosphorylation, sulfation or acetylation using SEQUEST.
Peptide sequence Modification
Modified
residue digestion matches highest Xcorr charge
APETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPY Phosphorylation Serine 33 Chymotrypsin 1 4,53 +5
APETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSY Phosphorylation Serine 33 Chymotrypsin 2 4,74 +5
APETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSYVAL Phosphorylation Serine 33 Chymotrypsin 3 5,12 +4
LAPETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSY Phosphorylation Serine 33 Chymotrypsin 2 5,04 +4
LAPETGRTVKEPEGPPPSPGKGGGGGGGTAPEKPDPAQKPPYSYVAL Phosphorylation Serine 33 Chymotrypsin 2 5,06 +4
EPEGPPPSPGK Phosphorylation Serine 33 Trypsin 33 2,66 +2
TVKEPEGPPPSPGK Phosphorylation Serine 33 Trypsin 24 4,14 +2
LNNSWPLPQPPSPMPY Phosphorylation Serine 211/
Tyrosine 215
Chymotrypsin 27 3,94 +2
NNSWPLPQPPSPMPY Phosphorylation Serine 211/
Tyrosine 215
Chymotrypsin 16 3,41 +2
AScQMAAAAAAAAAAAAAAGPGSPGAAAVVKGL Phosphorylation Serine 238 Chymotrypsin 5 6,21 +3
AAAAAAAAAAAAAAGPGSPGAAAVVKGL Phosphorylation Serine 238 Chymotrypsin 19 7,47 +3
AAAAAAAAAAAAAAGPGSPGAAAVVKGLAGPAASY Phosphorylation Serine 238 Chymotrypsin 6 6,67 +3
HAAAAPPPAPPHHGAAAPPPGQLSPASPATAAPPAPAPTSAPGLQF Phosphorylation Serine 323/
Serine 326/
Threonine 329
Chymotrypsin 5 4,45 +3
SPASPATAAPPAPAPTSAPGLQF Phosphorylation Serine 323/
Serine 326/
Threonine 329
Chymotrypsin 5 3,38 +2
MMASYPEPEDAAGAL Sulfation Serine 4/
Tyrosine 5
Chymotrypsin 8 2,47 +2
MMASYPEPEDAAGALL Sulfation Serine 4/
Tyrosine 5
Chymotrypsin 1 2,19 +2
MMASYPEPEDAAGALLAPETGR Sulfation Serine 4/
Tyrosine 5
Trypsin 12 4,74 +3
ASYPEPEDAAGAL Sulfation Serine 4/
Tyrosine 5
Chymotrypsin 17 3,38 +2
ASyPEPEDAAGALL Sulfation Serine 4/
Tyrosine 5
Chymotrypsin 8 2,61 +2
KGWQNSIR Acetylation Lysine 96 Trypsin 4 2,2 +2
TLDPACEDMFEKGNY Acetylation Lysine 140 Chymotrypsin 1 2,63 +2
DHDSKTGALHSRLDQGQF Acetylation Lysine 366 Chymotrypsin 1 3,17 +2
Each line represents a group of matches reaching our quality cut-off corresponding to the same peptide sequence with the indicated modification. SEQUEST matches
were selected to have a XCorr.2 when peptide charge was +2, .2.5 with peptide charge +3, .3 with peptide charge +4, and .4 with peptide charge .+5. Detail of all
peptide matches (modified and unmodified) obtained by both search engines is available as supplementary information (Table S1).
doi:10.1371/journal.pone.0025463.t002
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The yeast two-hybrid screen using the FOXL2 bait was carried
out by Dualsystems Biotech AG, Zurich, Switzerland. The bait
construct for yeast two-hybrid screening was made by subcloning a
full length FOXL2 cDNA into the vector pLexA-DIR (Dualsys-
tems Biotech AG, Zurich, Switzerland). We used a mutated
version of FOXL2 (H104N) that is hypomorphic and does not lead
to aggregation, in order to avoid the toxicity displayed by the wild-
type protein in yeast. The bait construct was transformed into the
strain NMY32 (MATa his3D200 trp1-901 leu2-3,112 (lexAop)8-
ADE2 LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ GAL4) using
standard procedures. Correct expression of the bait was verified
by western blotting of cell extracts using a mouse monoclonal
antibody directed against the LexA domain (Dualsystems Biotech,
Switzerland). The absence of self-activation was verified by co
transformation of the bait together with a control prey and
selection on minimal medium lacking the amino acids tryptophan,
leucine and histidine (selective medium). For the yeast two-hybrid
screen, the bait was cotransformed together with a mouse ovary
cDNA library (8.106 independent clones) into NMY32. Positive
transformants were tested for beta-galactosidase activity using
a PXG b-galactosidase assay (Dualsystems Biotech) and when
positive were considered to be true interatactants. Library
plasmids were isolated from positive clones. The identity of
positive interactors was determined by sequencing.
Cell culture and transient transfections
Granulosa-like KGN cells were used to perform functional
analysis as they are close to ovarian granulosa cells where FOXL2
is normally expressed. They were grown in DMEM-F12 medium,
supplemented with 10% FBS and 1% penicillin/streptomycin
(Invitrogen-Gibco). COS-7 cells were used in experiments where
high level of transfection were required (to score protein
localization or in immunoprecipitation assays). They were grown
in DMEM medium supplemented with 10% FBS and 1%
penicillin/streptomycin. Cells were seeded 16 h prior to transfec-
tion at a density of 4610
4 cells.cm
22 (KGN cells) or 2.5610
4
cells.cm
22 (COS-7 cells), and transfected using the calcium-
phosphate method (COS-7) or Lipofectamine 2000 reagent (KGN)
(Invitrogen) [65].
Luciferase assays
Luciferase assays were performed in KGN cells as previously
described [47]. Cells seeded at 50% confluence in 96-well plates
were transfected with 40 ng/well reporter, 5 ng/well transfection
control and 20 ng/well of each plasmid using Lipofectamine 2000
reagent (Invitrogen) (1 uL/well), then lysed 24 h after transfec-
tion and analyzed with the Dual-Glo Luciferase Assay System
(Promega) according to manufacturer’s instruction. Relative
luciferase units values given for all experiments are the means
of values obtained from 6 biologically independent replicates,
and represent the ratio of firefly luciferase activity over Renilla
luciferase activity in the samples. Statistical significance was
estimated by a Student t-test. Errors bars represent the Standard
Deviation.
Immunoprecipitation and Antibodies
COS-7 cells were lysed 48 h after transfection in Lysis Buffer
(50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
pH 7.6) supplemented with protease inhibitors (PMSF 0.1 mM
and Complete mini EDTA-free cocktail, Roche), phosphatase
inhibitors (PhosSTOP, Roche), deacetylase inhibitors (TSA 1 mM
and nicotinamide 5 mM) and N-ethylmaleimide 12,5 mM.
Clarified lysates were immunoprecipitated using anti-FLAG M2
magnetic beads (Sigma) according to manufacturer’s instructions.
Precipitated proteins were eluted in 50 mM Tris 150 mM NaCl
pH 7.6 and 150 ng/uL 3XFLAG peptide (Sigma). Eluates were
then separated by SDS-PAGE using NuPage Bis-Tris 4–12% Gels
and MOPS-SDS Running Buffer (Invitrogen) and proteins were
electrotransfered onto PVDF membranes (Hybond-P, GE Health-
care). The C-terminal peptide anti-FoxL2 polyclonal rabbit
antibody has been described previously [1]. Monoclonal anti-
acetylated lysine antibody was purchased from Cell Signaling
technologies and used at a 1/1000 dilution. For tandem mass
spectrometry, eluted proteins were separated by SDS-PAGE and
stained with coomassie. The 50 kDa major band and eluate were
both digested with trypsin or chymotrypsin (Sigma) according to
the manufacturer’s instruction.
Tandem mass spectrometry
Digested peptides were separated on a nanoLC column using a
70 min gradient (for in gel digestion) and a 90 min gradient
(for eluate digestion) and analysed in a LTQ Orbitrap Velos
spectrometer (Thermo Fisher Scientific) with CID fragmentation.
MS/MS spectra were analyzed with Mascot and Sequest, using a
human database based on the Uniprot Knowledge Base, with a
precursor match preference of 10 ppm and a fragment match
tolerance of 0.8 Da. Modifications initially included in the
research were phosphorylation of serines/threonines/tyrosines
(+79.966 Da), acetylation of lysines (+42.010 Da), oxidation
of methionines (+15.994 Da) and modification of cysteines
with N-ethylmaleimide (+125.048 Da) or Carboxyamidomethyl
(+57.021 Da). Peptides identified with FDR,0.01 by both engines
were selected. Peptides identified only by one of the engines
(including lysine 140 acetylation) were manually inspected and
validated.
Fluorescence microscopy of transfected cells and
immunofluorescence
Cells were seeded onto 1 cm diameter glass coverslips in 24-well
plates and transfected with expression vectors of interest, as
described previously. Forty eight hours after transfection, cells
were fixed in Histofix (Trend Scientific, Inc), and DNA was
stained with Hoechst 33342 (Invitrogen). For immunofluorescence
experiments, COS-7 cells were transfected as above, using the
FOXL2-GFP and the SUMO1-His6 constructs. Forty eight hours
after transfection, cells were washed with PBS, fixed for 15 min
Figure 6. Transactivation ability and localisation rate to PML NBs of non-modifiable mutants. A and B) Luciferase assays in KGN cells
transfected with Per2-luc and pSODluc-3340 (40 ng/well), respectively, with or without overexpression of wild-type FOXL2 or various FOXL2 alleles
(20 ng/well), each one corresponding to a substitution of a potentially modified residue by an amino-acid simulating the non-modified residue. Each
value is representative of six biological replicates. Error bars represent the SEM. Statistical significance in Student t-tests, compared to FOXL2-WT:
*: p,0.05. Hyperactivities of FOXL2-S326A on Per2-luc and FOXL2-K366R on pSODluc-3340 compared to FOXL2-WT were seen only in one
experiment out of four. C) Quantification of cells presenting subnuclear structures in COS-7 expressing wild-type FOXL2-GFP with or without
overexpression of SUMO1 or SENP2, or the same FOXL2-GFP alleles as above. At least 200 GFP-positive cells were scanned per condition (in groups of
at least 50 cells to estimate the standard deviations). Error bar: SEM. Statistical significance in Student t-tests, compared to FOXL2-WT: *: p,0.05.
doi:10.1371/journal.pone.0025463.g006
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PBS/1%Triton-X/10%FBS, and then blocked with 5% nonfat milk
and 2% FBS in PBS/0.1%Tween 20. Cells were incubated
overnight in the indicated antibody. Cells were then washed three
times in PBS, and incubated for 1 h in an appropriate secondary
antibody (diluted 1/500). In all cases, the coverslips were mounted
on glass slides with DakoCytomaton (Dako). Cells were visualized by
epifluorescence microscopy using a Leitz Aristoplan microscope,
with a Leitz objective lens6100/1.37 Oil with a numerical aperture
of 0.17. Image acquisition was done with a JVC KX-F70B camera.
Weusedthe followingantibodies with theindicated dilution:chicken
anti-pan-PML ([51] a generous gift from Prof. H. de The ´) 1/500,
mouse anti-SUMO1 (Zymed) 1/500, mouse anti-HSV tag (Nova-
gen) 1/1000, mouse anti-SC35 (Sigma) 1/2000, rabbit anti-RNA
Helicase A (Abcam) 1/1000, mouse anti-Pol2 (Covance) 1/1000,
mouse anti-2,2,7-trimethylGuanosine cap (Calbiochem) 1/100.
Fluorescence Recovery After Photobleaching (FRAP)
experiments
FRAP experiments were conducted as previously [47]. Photo-
bleaching experiments were performed 48 hours after transfec-
tion of COS-7 cells using a LEICA TCS SP2 AOBS confocal
microscope. A small section of the nucleoplasm and of a nuclear
body (when relevant) were bleached, and 50 images were collected
every 1.635 s after bleaching. Data were collected from 10 to 15
different cells for each condition. Image analysis was performed
with ImageJ software. Values for t1/2 are given 6SEM.
Supporting Information
Figure S1 FRAP experiments on COS-7 nuclei transfect-
ed with FOXL2-GFP alone and SUMO1-FOXL2-GFP. For
each condition: the leftmost panel shows GFP signal prior to
bleaching. The second panel shows GFP signal immediately after
bleaching (t=1 s). The bleached portion(s) appears as dark
regions. Black arrowheads indicate bleached nucleoplasmic
portions and white arrowheads the bleached nuclear subcompart-
ment. The two other panels show fluorescence recovery after 10
and 30 s. Complete recovery was achieved in all cases.
(TIF)
Figure S2 SUMO-FOXL2 Bodies are not enriched in SC-
35, Pol2, RNA Helicase A or TMG-capped RNA. COS-7
cells were transfected with FOXL2-GFP and SUMO1. A
representative cell with SUMO-FOXL2 Bodies is shown. SC-35
(i), RNA HA (ii), Pol2 (iii) and TMG-capped RNAs (iv) localization
were detected by immunofluorescence, and DNA by Hoechst
33342 staining, pointing to an absence of colocalisation with
SUMO-FOXL2 Bodies. This excludes the hypothesis that
SUMO-FOXL2 Bodies are splicing factories, nucleoli, Cajal
Bodies, gems or transcription factories.
(TIF)
Table 3. Components of the post-translational machinery
present in PML NBs.
Type of
modification Protein name
Uniprot accession
number effect
Acetylation CBP Q92793 +
p300 Q09472 +
TIP60 Q92993 +
HDAC1 Q13547 2
HDAC2 Q92769 2
HDAC3 O15379 2
HDAC7 Q8WUI4 2
SIRT1 Q96EB6 2
Methylation PRMT1 Q99873 +
EZH2 Q15910 +
Phosphorylation CK1 P48729 +
CK2 P68400 +
MNK2b Q9HBH9 +
p38 Q16539 +
IKKe Q14164 +
ATR Q13535 +
ATM Q13315 +
mTOR P42345 +
STK6 O14965 +
CHK2 O96017 +
HIPK1 Q86Z02 +
HIPK2 Q9H2X6 +
HIPK3 Q9H422 +
ZIPK O43293 +
SUMOylation SUMO-1 P63165
SUMO-2 P61956
SUMO-3 P55854
UBA2 Q9UBT2 +
UBC9 P63279 +
PIASy Q8N2W9 +
RANBP2 P49792 +
MMS21 Q96MF7 +
SENP1 Q9P0U3 2
SENP2 Q9HC62 2
SENP5 Q96HI0 2
Ubiquitination TOPORS Q9NS56 +
BRCA1 P38398 +
RNF6 Q9Y252 +
RBCK1 Q9BYM8 +
MDM2 Q00987 +
E6AP Q05086 +
FBX3/SCF Q9UK99 +
CULLIN1 Q13616 +
SKP1 P63208 +
PLZF Q05516 +
UBP7 Q93009 2
Enzymes involved in post-translational modifications of proteins and described
as associated with PML Nuclear Bodies, according to Van Damme et al. [34].
These proteins represent about 30% of all proteins associated with PML NBs,
highlighting a potential integrative role of PML NBs in post-translational
maturation of nuclear proteins. Proteins followed by a + sign are mainly
involved in the transfer of post-translational moieties to protein substrates (e.g.
kinases), whereas those with a 2 sign are associated to protein demodification
(e.g. phosphatases). Uniprot accession IDs are in italic.
doi:10.1371/journal.pone.0025463.t003
Table 3. Cont.
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EPEPPPSPGK in its unmodified (upper panel) and
phosphorylated form (lower panel). Proeminent neutral
loss fragments corresponding to loss of H3P04, H3P04+H2O,
H3P04+NH3 or H3P04+H2O+NH3 are present in the second
spectrum (in green). Fragments attributed to the y-series of ions in
the first spectrum (in blue) are conserved in the second spectrum
(with the exception of y5) and bear the 80 Da modification,
making it possible to localize it in the Pro-Pro-Ser sugfragment (y3
does not bear the modification as y6 does). Fragments attributed to
the b-series of ions in the first spectrum (in red), most of them
affected by an H2O neutral loss are also well conserved and
confirm the localisation of the modification. Indeed b2 to b6
fragments are unaffected in size, whereas b8 is found with a
218 Da weight due to loss of an H2O group along with the
phosphate (+80 Da–98 Da). This again localises the modification
in the Pro-Ser subfragment and confirms the attribution.
(TIF)
Figure S4 Spectrum attribution of the chymotryptic
peptide AAAAAAAAAAAAAAGPGSPGAAAVVKGL in its
unmodified (upper panel) and phosphorylated form
(lower panel). Neutral loss fragments characteristic of th pho-
sphorylation are present but with pour abundance (in green).
Spectra are extremely complex due to the size of the peptide but
many peaks are attributed giving these peptides very high scores
(XCorr=6.97 for the upper spectrum, XCorr=7.16 for the lower
one) and little doubt about their attribution. Most peaks of the y-
series (in blue) bearing the modification are present and well
conserved between spectra, which allows to localize the modifi-
cation in the Pro-Gly-Ser subfragment (y10 does not bear the
modification, y13 does), further confirming the attribution.
(TIF)
Figure S5 Spectrum attribution of the chymotryptic
peptide LNNSWPLPQPPSPMPY in its unmodified (up-
per panel) and phosphorylated form (lower panel).
Neutral loss fragments are detected (in green) but are very minor.
Peaks of the y-series (in blue) y7, y9, y11 and y12 are well
conserved and bear the 80 Da modification in the second
spectrum, allowing to localize it in the Pro-Pro-Ser-Pro-Met-Pro-
Tyr subfragment. The b-series of ions are well conserved between
spectra but give little informations about the modification position.
Only small peaks attributed to y2 and b14 that are conserved
between spectra suggest that the serine may more likely bear the
modification (indeed y2 appears unshifted whereas b14 is shifted
by 80 Da). However the intensity of this peaks does not allow to
strictly conclude that serine 211 is the modified residue in this case.
(TIF)
Figure S6 Spectrum attribution of the chymotryptic
peptide SPASPATAAPPAPAPTSAPGLQF in its unmodi-
fied (upper panel) and phosphorylated form (lower
panel). Some neutral loss fragment (in green) characteristic of
phosphorylation may be observed, but are once again of very low
abundance. The fragmentation pattern is overall rather poor, but
the main peaks are well conserved between spectra, notably y14
and y15 (in blue) and b9 and b14 (in red). This allows to localize
the modification in the Ser-Pro-Ala-Ser-Pro-Ala-Thr-Ala-Ala
subfragment, which still contains three possible sites for phos-
phorylation. Indeed both b9 and b14 are detected with both a
+80 Da and a 218 Da shift in the second spectrum, whereas y14
and y15 are unshifted. A small peak attributed to y19 and
unshifted between the spectra suggests that the modification is
localised in the Ser-Pro-Ala-Ser subfragment, eliminating Thr329
as a phosphorylated residue, but this peak has a too low intensity
to strictly conclude. According to the GPS 2.1 phospohrylation
prediction tool, Ser326 is the residue most likely to be
phosphorylated.
(TIF)
Figure S7 Spectrum attribution of the chymotryptic
peptide ASYPEPEDAAGAL in its unmodified (upper
panel) and sulfated form (lower panel). b-series of ions (in
red) are well conserved between the two spectrum, with a 80 Da
shift in the second spectrum. The doubly charged ions of the b-
s e r i e sa r eh o w e v e rm u c hm o r ei n t e n s ei nt h es e c o n ds p e c t r u m ,
compared to the monocharged ions. For example the intensity
ratio of b122+ over b12+ is close to 3 in the first spectrum, and
c l o s et o3 0i nt h es e c o n do n e .O t h e ri o n so ro t h e rs p e c t r aa r e
coherent with this observation .T h ey - s e r i e so fi o n si so n l y
represented by two proeminent peaks (in blue) in the first
spectrum, corresponding to fragmentations before the two
prolines of the peptide. This suggests that one of the peptide
positive charges is solvated N-terminally of prolines, favoring
fragmentation at these points, which is coherent with the higher
pKa of proline amino function, compared to other amino acids.
These two peaks completely disappear in the second spectrum,
suggesting that the modification sequesters the positive charge,
presumably through hydrogen bonding between the sulphate
oxygens and carbonyl groups of the primary chain. This is also
coherent with the prevalence of doubly-charged fragments in
t h es e c o n ds p e c t r u m .O n ea d d i t ional peak, attributed to y7+-
NH3 by MASCOT appears in the second spectrum. Compar-
ison with other spectra shows that this attribution is erroneous
and that this fragment bears two positive charges. It may be due
to an unusual c-ion, corresponding to the neutral loss of the last
amino-acid.
(TIF)
Figure S8 Spectrum attribution of the tryptic peptide
KGWQNSIR in its unmodified (upper panel) and
acetylated form (lower panel). The monocharged y-series of
ions (in blue) is well conserved between spectra and goes from y1
to y7, all peaks being unshifted, which localize the 42 Da mass
shift to the first amino acid of the sequence, which indeed is a
lysine. The b-series of ions (in red) are much less intense, but the
most intense peaks of the first spectrum (b2, b6, b7) are found in
the second spectrum shifted by 42 Da, confirming the presence of
an acetyl group on the N-terminal lysine of this peptide.
(TIF)
Figure S9 Spectrum attribution of the chymotryptic
peptide TLDPACEDMFEKGNY in its unmodified (upper
panel) and acetylated form (lower panel). Most intense
peaks of the y-series (in blue) and b-series (in red) are well
conserved between the two spectra but do not allow for a very
precise localisation of the modification. A more intense acetylated
precursor could help obtaining more detailed fragmentation
spectra and confirm the localisation of the modification.
(TIF)
Figure S10 Spectrum attribution of the chymotryptic
peptide DHDSKTGALHSRLDQGQF in its unmodified
(upper panel) and acetylated form (lower panel). The
monocharged y-series of ions (in blue) allows to localize the 42 Da
modification in the Asp-His-Asp-Ser-Lys subfragment as peaks
corresponding to y9 to y13 fragment are well defined and
unshifted between spectra. A more intense acetylated precursor
could help obtaining more detailed fragmentation spectra and
confirm the localisation of the modification.on lysine 366.
(TIF)
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Mascot and SEQUEST search engines. Peptide matches
attributed to FOXL2 and presenting a peptide score higher than
20 (for Mascot) or have a XCorr.2 when peptide charge was +2,
.2.5 with peptide charge +3, .3 with peptide charge +4, and .4
with peptide charge .+5 (for SEQUEST) are listed in first (for
Mascot) and second (for SEQUEST) worksheet. The predicted
peptide modification, score, charge, precursor m/z, precursor
MH+, predicted-to-measured mass difference (DM), column
retention time and origin sample are indicated for each peptide
match. Note that sulfation was not included as a possible
modification, since search engines do not take into account the
precursor mass and so can not distinguish between phosphoryla-
tion and sulfation. However, attribution of a phosphorylation on
serine 4 or tyrosine 5 was systematically associated to a DM close
to 29 mmu, corresponding to the difference between phosphate
and sulfonate group.
(XLS)
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